PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS-19, COMPRISING CAS13 PROTEIN AND CRRNA
The present invention relates to a pharmaceutical composition for preventing or treating coronavirus-19, comprising Cas13 proteins and crRNA. Particularly, Cas13b and scRNA, which targets the RdRp gene region of ORF1b of SARS-CoV-2, of the present invention, are not cytotoxic and have the excellent...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | YU, Daseuli HEO, Won Do YU, Jeonghye |
| description | The present invention relates to a pharmaceutical composition for preventing or treating coronavirus-19, comprising Cas13 proteins and crRNA. Particularly, Cas13b and scRNA, which targets the RdRp gene region of ORF1b of SARS-CoV-2, of the present invention, are not cytotoxic and have the excellent ability to degrade SARS-CoV-2 RNA, and thus can be effectively used as therapeutic agents for coronavirus disease 19.
La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement du coronavirus-19, comprenant des protéines Cas13 et de l'ARNcr. En particulier, Cas13b et ARNsc, qui cible la région du gène RdRp d'ORF1b du SARS-CoV-2, de la présente invention, ne sont pas cytotoxiques et ont une excellente capacité à dégrader l'ARN du SARS-CoV-2, et peuvent ainsi être utilisés efficacement en tant qu'agents thérapeutiques pour la maladie du coronavirus 19.
본 발명은 Cas13 단백질 및 crRNA를 포함하는 코로나바이러스감염증-19 예방 또는 치료용 약학적 조성물에 관한 것으로, 구체적으로 본 발명의 Cas13b 및 SARS-CoV-2의 ORF1b의 RdRp 유전자 부분을 표적으로 하는 scRNA는 세포 독성이 없고, SARS-CoV-2의 RNA를 분해하는 능력이 우수하므로 코로나바이러스감염증-19의 치료제로 유용하게 사용될 수 있다. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2022250503A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2022250503A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2022250503A13</originalsourceid><addsrcrecordid>eNqNi7EKwkAQRNNYiPoPB7YGLhdSWC7nxSyY3bB3iWUIcmIhGoj_jyH4AVYzw5u3Th5NBVKDdW1ACxdluW7YY0AmVbKoRlznKCCd1byCOFi6ZWGCDqX1aXY8LJqgXxD4LJ89Dg5JAZ2UFSHYJqv78Jzi7pebZF-6YKs0ju8-TuNwi6_46a9stDGm0IXOIcv_e30BGLk2hg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS-19, COMPRISING CAS13 PROTEIN AND CRRNA</title><source>esp@cenet</source><creator>YU, Daseuli ; HEO, Won Do ; YU, Jeonghye</creator><creatorcontrib>YU, Daseuli ; HEO, Won Do ; YU, Jeonghye</creatorcontrib><description>The present invention relates to a pharmaceutical composition for preventing or treating coronavirus-19, comprising Cas13 proteins and crRNA. Particularly, Cas13b and scRNA, which targets the RdRp gene region of ORF1b of SARS-CoV-2, of the present invention, are not cytotoxic and have the excellent ability to degrade SARS-CoV-2 RNA, and thus can be effectively used as therapeutic agents for coronavirus disease 19.
La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement du coronavirus-19, comprenant des protéines Cas13 et de l'ARNcr. En particulier, Cas13b et ARNsc, qui cible la région du gène RdRp d'ORF1b du SARS-CoV-2, de la présente invention, ne sont pas cytotoxiques et ont une excellente capacité à dégrader l'ARN du SARS-CoV-2, et peuvent ainsi être utilisés efficacement en tant qu'agents thérapeutiques pour la maladie du coronavirus 19.
본 발명은 Cas13 단백질 및 crRNA를 포함하는 코로나바이러스감염증-19 예방 또는 치료용 약학적 조성물에 관한 것으로, 구체적으로 본 발명의 Cas13b 및 SARS-CoV-2의 ORF1b의 RdRp 유전자 부분을 표적으로 하는 scRNA는 세포 독성이 없고, SARS-CoV-2의 RNA를 분해하는 능력이 우수하므로 코로나바이러스감염증-19의 치료제로 유용하게 사용될 수 있다.</description><language>eng ; fre ; kor</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221201&DB=EPODOC&CC=WO&NR=2022250503A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221201&DB=EPODOC&CC=WO&NR=2022250503A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>YU, Daseuli</creatorcontrib><creatorcontrib>HEO, Won Do</creatorcontrib><creatorcontrib>YU, Jeonghye</creatorcontrib><title>PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS-19, COMPRISING CAS13 PROTEIN AND CRRNA</title><description>The present invention relates to a pharmaceutical composition for preventing or treating coronavirus-19, comprising Cas13 proteins and crRNA. Particularly, Cas13b and scRNA, which targets the RdRp gene region of ORF1b of SARS-CoV-2, of the present invention, are not cytotoxic and have the excellent ability to degrade SARS-CoV-2 RNA, and thus can be effectively used as therapeutic agents for coronavirus disease 19.
La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement du coronavirus-19, comprenant des protéines Cas13 et de l'ARNcr. En particulier, Cas13b et ARNsc, qui cible la région du gène RdRp d'ORF1b du SARS-CoV-2, de la présente invention, ne sont pas cytotoxiques et ont une excellente capacité à dégrader l'ARN du SARS-CoV-2, et peuvent ainsi être utilisés efficacement en tant qu'agents thérapeutiques pour la maladie du coronavirus 19.
본 발명은 Cas13 단백질 및 crRNA를 포함하는 코로나바이러스감염증-19 예방 또는 치료용 약학적 조성물에 관한 것으로, 구체적으로 본 발명의 Cas13b 및 SARS-CoV-2의 ORF1b의 RdRp 유전자 부분을 표적으로 하는 scRNA는 세포 독성이 없고, SARS-CoV-2의 RNA를 분해하는 능력이 우수하므로 코로나바이러스감염증-19의 치료제로 유용하게 사용될 수 있다.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi7EKwkAQRNNYiPoPB7YGLhdSWC7nxSyY3bB3iWUIcmIhGoj_jyH4AVYzw5u3Th5NBVKDdW1ACxdluW7YY0AmVbKoRlznKCCd1byCOFi6ZWGCDqX1aXY8LJqgXxD4LJ89Dg5JAZ2UFSHYJqv78Jzi7pebZF-6YKs0ju8-TuNwi6_46a9stDGm0IXOIcv_e30BGLk2hg</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>YU, Daseuli</creator><creator>HEO, Won Do</creator><creator>YU, Jeonghye</creator><scope>EVB</scope></search><sort><creationdate>20221201</creationdate><title>PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS-19, COMPRISING CAS13 PROTEIN AND CRRNA</title><author>YU, Daseuli ; HEO, Won Do ; YU, Jeonghye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2022250503A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; kor</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>YU, Daseuli</creatorcontrib><creatorcontrib>HEO, Won Do</creatorcontrib><creatorcontrib>YU, Jeonghye</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>YU, Daseuli</au><au>HEO, Won Do</au><au>YU, Jeonghye</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS-19, COMPRISING CAS13 PROTEIN AND CRRNA</title><date>2022-12-01</date><risdate>2022</risdate><abstract>The present invention relates to a pharmaceutical composition for preventing or treating coronavirus-19, comprising Cas13 proteins and crRNA. Particularly, Cas13b and scRNA, which targets the RdRp gene region of ORF1b of SARS-CoV-2, of the present invention, are not cytotoxic and have the excellent ability to degrade SARS-CoV-2 RNA, and thus can be effectively used as therapeutic agents for coronavirus disease 19.
La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement du coronavirus-19, comprenant des protéines Cas13 et de l'ARNcr. En particulier, Cas13b et ARNsc, qui cible la région du gène RdRp d'ORF1b du SARS-CoV-2, de la présente invention, ne sont pas cytotoxiques et ont une excellente capacité à dégrader l'ARN du SARS-CoV-2, et peuvent ainsi être utilisés efficacement en tant qu'agents thérapeutiques pour la maladie du coronavirus 19.
본 발명은 Cas13 단백질 및 crRNA를 포함하는 코로나바이러스감염증-19 예방 또는 치료용 약학적 조성물에 관한 것으로, 구체적으로 본 발명의 Cas13b 및 SARS-CoV-2의 ORF1b의 RdRp 유전자 부분을 표적으로 하는 scRNA는 세포 독성이 없고, SARS-CoV-2의 RNA를 분해하는 능력이 우수하므로 코로나바이러스감염증-19의 치료제로 유용하게 사용될 수 있다.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; kor |
| recordid | cdi_epo_espacenet_WO2022250503A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS-19, COMPRISING CAS13 PROTEIN AND CRRNA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A11%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=YU,%20Daseuli&rft.date=2022-12-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2022250503A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |